Literature DB >> 21826111

Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.

Nathan A Gray1, Robert D Odze, Stuart Jon Spechler.   

Abstract

OBJECTIVES: Endoscopic ablation of Barrett's esophagus can bury metaplastic glands under a layer of neosquamous epithelium. To explore the frequency and importance of buried metaplasia, we have conducted a systematic review of reports on endoscopic ablation.
METHODS: We performed computerized and manual searches for articles on the results of photodynamic therapy (PDT) and radiofrequency ablation (RFA) for Barrett's esophagus. We extracted information on the number of patients treated, biopsy protocol, biopsy depth, and frequency of buried metaplasia.
RESULTS: We found 9 articles describing 34 patients with neoplasia appearing in buried metaplasia (31 after PDT). We found five articles describing a baseline prevalence of buried metaplasia (before ablation) ranging from 0% to 28%. In 22 reports on PDT for 953 patients, buried metaplasia was found in 135 (14.2%); in 18 reports on RFA for 1,004 patients, buried metaplasia was found in only 9 (0.9%). A major problem limiting the conclusions that can be drawn from these reports is that they do not describe specifically how frequently biopsy specimens contained sufficient subepithelial lamina propria to be informative for buried metaplasia.
CONCLUSIONS: Endoscopic ablation can bury metaplastic glands with neoplastic potential but, even without ablation, buried metaplasia often is found in areas where Barrett's epithelium abuts squamous epithelium. Buried metaplasia is reported less frequently after RFA than after PDT. However, available reports do not provide crucial information on the adequacy of biopsy specimens and, therefore, the frequency and importance of buried metaplasia after endoscopic ablation remain unclear.

Entities:  

Mesh:

Year:  2011        PMID: 21826111      PMCID: PMC3254259          DOI: 10.1038/ajg.2011.255

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  56 in total

1.  Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness.

Authors:  Krish Ragunath; Neville Krasner; V Sankara Raman; Mustafa T Haqqani; Ceri J Phillips; Ivy Cheung
Journal:  Scand J Gastroenterol       Date:  2005-07       Impact factor: 2.423

2.  Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.

Authors:  B F Overholt; M Panjehpour; J M Haydek
Journal:  Gastrointest Endosc       Date:  1999-01       Impact factor: 9.427

3.  Does ablative therapy for Barrett esophagus affect the depth of subsequent esophageal biopsy as compared with controls?

Authors:  Bergein F Overholt; Patrick J Dean; Joseph A Galanko; Charles J Lightdale
Journal:  J Clin Gastroenterol       Date:  2010 Nov-Dec       Impact factor: 3.062

4.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

5.  Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer.

Authors:  Christophoros N Foroulis; James A C Thorpe
Journal:  Eur J Cardiothorac Surg       Date:  2005-12-06       Impact factor: 4.191

6.  Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in barrett esophagus after endoscopic resection.

Authors:  F Peters; M Kara; W Rosmolen; M Aalders; F Ten Kate; K Krishnadath; J van Lanschot; P Fockens; J Bergman
Journal:  Endoscopy       Date:  2005-05       Impact factor: 10.093

7.  Squamous islands in Barrett's esophagus: what lies underneath?

Authors:  P Sharma; T G Morales; A Bhattacharyya; H S Garewal; R E Sampliner
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

8.  Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation.

Authors:  C J Kelty; R Ackroyd; N J Brown; T J Stephenson; C J Stoddard; M W R Reed
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

9.  Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.

Authors:  H C Wolfsen; L L Hemminger; M B Wallace; K R Devault
Journal:  Aliment Pharmacol Ther       Date:  2004-11-15       Impact factor: 8.171

10.  Endoscopic laser ablation of nondysplastic Barrett's epithelium: is it worthwhile?

Authors:  L Bonavina; C Ceriani; A Carazzone; A Segalin; S Ferrero; A Peracchia
Journal:  J Gastrointest Surg       Date:  1999 Mar-Apr       Impact factor: 3.267

View more
  47 in total

1.  Sixteen-year follow-up of Barrett's esophagus, endoscopically treated with argon plasma coagulation.

Authors:  Mariana Milashka; Annabelle Calomme; Jean Luc Van Laethem; Daniel Blero; Pierre Eisendrath; Olivier Le Moine; Jacques Devière
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

2.  The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

Authors:  Chin Hur; Sung Eun Choi; Joel H Rubenstein; Chung Yin Kong; Norman S Nishioka; Dawn T Provenzale; John M Inadomi
Journal:  Gastroenterology       Date:  2012-05-21       Impact factor: 22.682

3.  Label-free multi-photon imaging of dysplasia in Barrett's esophagus.

Authors:  Soroush Mehravar; Bhaskar Banerjee; Hemant Chatrath; Babak Amirsolaimani; Krunal Patel; Charmi Patel; Robert A Norwood; Nasser Peyghambarian; Khanh Kieu
Journal:  Biomed Opt Express       Date:  2015-12-16       Impact factor: 3.732

Review 4.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

Review 5.  Low grade dysplasia in Barrett's esophagus: Should we worry?

Authors:  Vamshi P Jagadesham; Clive J Kelty
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

6.  Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells.

Authors:  Qiuyang Zhang; Agoston T Agoston; Thai H Pham; Wei Zhang; Xi Zhang; Xiaofang Huo; Sui Peng; Manisha Bajpai; Kiron Das; Robert D Odze; Stuart J Spechler; Rhonda F Souza
Journal:  Gastroenterology       Date:  2018-09-27       Impact factor: 22.682

Review 7.  Post-ablation surveillance in Barrett's esophagus: A review of the literature.

Authors:  Matthew W Stier; Vani J Konda; John Hart; Irving Waxman
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

Review 8.  Barrett's esophagus in 2016: From pathophysiology to treatment.

Authors:  Irene Martinucci; Nicola de Bortoli; Salvatore Russo; Lorenzo Bertani; Manuele Furnari; Anna Mokrowiecka; Ewa Malecka-Panas; Vincenzo Savarino; Edoardo Savarino; Santino Marchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

9.  A survey of expert follow-up practices after successful endoscopic eradication therapy for Barrett's esophagus with high-grade dysplasia and intramucosal adenocarcinoma.

Authors:  Aarti O Bedi; Richard S Kwon; Joel H Rubenstein; Cyrus R Piraka; Grace H Elta; James M Scheiman; B Joseph Elmunzer
Journal:  Gastrointest Endosc       Date:  2013-05-24       Impact factor: 9.427

10.  Endoscopic mucosal resection of Barrett's esophagus detects high prevalence of subsquamous intestinal metaplasia.

Authors:  Patrick Yachimski; Chanjuan Shi; James C Slaughter; Mary Kay Washington
Journal:  World J Gastrointest Endosc       Date:  2013-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.